Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. [electronic resource]
Producer: 20100602Description: 1073-81 p. digitalISSN:- 1432-0851
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Cell Line, Tumor
- Drug Synergism
- Female
- Male
- Mammary Neoplasms, Experimental -- drug therapy
- Mice
- Mice, Inbred BALB C
- Mice, Transgenic
- Oligodeoxyribonucleotides -- administration & dosage
- Pyrazines -- administration & dosage
- Rats
- Receptors, TNF-Related Apoptosis-Inducing Ligand -- agonists
- TNF-Related Apoptosis-Inducing Ligand -- administration & dosage
- Toll-Like Receptor 9 -- agonists
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.